Ind-Swift [INDSWFTLAB] vs Sakar Healthcare [SAKAR] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Ind-Swift Laboratories Ltd. wins in 11 metrics, Sakar Healthcare Ltd. wins in 7 metrics, with 0 ties. Ind-Swift Laboratories Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Ind-Swift Laboratories Ltd. | Sakar Healthcare Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 4.00 | 54.56 | Ind-Swift Laboratories Ltd. |
| Price-to-Book Ratio | 0.84 | 4.56 | Ind-Swift Laboratories Ltd. |
| Debt-to-Equity Ratio | 1.69 | 28.06 | Ind-Swift Laboratories Ltd. |
| PEG Ratio | 0.05 | 0.45 | Ind-Swift Laboratories Ltd. |
| EV/EBITDA | -14.12 | 25.21 | Sakar Healthcare Ltd. |
| Profit Margin (TTM) | 41.86% | 10.90% | Ind-Swift Laboratories Ltd. |
| Operating Margin (TTM) | -3.09% | 17.37% | Sakar Healthcare Ltd. |
| EBITDA Margin (TTM) | N/A | 17.37% | N/A |
| Return on Equity | 21.35% | 6.13% | Ind-Swift Laboratories Ltd. |
| Return on Assets (TTM) | 17.41% | 4.21% | Ind-Swift Laboratories Ltd. |
| Free Cash Flow (TTM) | $-898.80M | $17.50M | Sakar Healthcare Ltd. |
| 1-Year Return | 50.16% | 163.04% | Sakar Healthcare Ltd. |
| Price-to-Sales Ratio (TTM) | 2.02 | 5.89 | Ind-Swift Laboratories Ltd. |
| Enterprise Value | $7.27B | $14.54B | Sakar Healthcare Ltd. |
| EV/Revenue Ratio | 1.23 | 6.28 | Ind-Swift Laboratories Ltd. |
| Gross Profit Margin (TTM) | 53.44% | 49.48% | Ind-Swift Laboratories Ltd. |
| Revenue per Share (TTM) | $76 | $104 | Sakar Healthcare Ltd. |
| Earnings per Share (Diluted) | $34.48 | $11.38 | Ind-Swift Laboratories Ltd. |
| Beta (Stock Volatility) | 0.67 | 0.11 | Sakar Healthcare Ltd. |
Ind-Swift Laboratories Ltd. vs Sakar Healthcare Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Ind-Swift Laboratories Ltd. | -0.73% | 3.25% | 20.88% | 18.01% | 65.79% | 78.85% |
| Sakar Healthcare Ltd. | 2.43% | 9.97% | 21.16% | 63.79% | 101.11% | 107.46% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Ind-Swift Laboratories Ltd. | 50.16% | 121.21% | 39.40% | 310.65% | 68.51% | 158.37% |
| Sakar Healthcare Ltd. | 163.04% | 219.98% | 457.01% | 1,273.50% | 1,273.50% | 1,273.50% |
Performance & Financial Health Analysis: Ind-Swift Laboratories Ltd. vs Sakar Healthcare Ltd.
| Metric | INDSWFTLAB | SAKAR |
|---|---|---|
| Market Information | ||
| Market Cap | ₹11.98B | ₹13.91B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 2,938,854 | 117,167 |
| 90 Day Avg. Volume | 1,379,551 | 89,299 |
| Last Close | ₹161.84 | ₹844.15 |
| 52 Week Range | ₹87.15 - ₹173.25 | ₹308.35 - ₹871.30 |
| % from 52W High | -6.59% | -3.12% |
| All-Time High | ₹296.50 (Dec 20, 2004) | ₹871.30 (Jun 01, 2026) |
| % from All-Time High | -45.42% | -3.12% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 16.41% | 0.62% |
| Quarterly Earnings Growth | 1,537.44% | 1.26% |
| Financial Health | ||
| Profit Margin (TTM) | 0.42% | 0.11% |
| Operating Margin (TTM) | -0.03% | 0.17% |
| Return on Equity (TTM) | 0.21% | 0.06% |
| Debt to Equity (MRQ) | 1.69 | 28.06 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹163.64 | ₹136.29 |
| Cash per Share (MRQ) | ₹51.43 | ₹0.10 |
| Operating Cash Flow (TTM) | ₹-213,518,000 | ₹223.74M |
| Levered Free Cash Flow (TTM) | ₹2.50B | ₹175.02M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | ₹0.00 | N/A |
Valuation & Enterprise Metrics Analysis: Ind-Swift Laboratories Ltd. vs Sakar Healthcare Ltd.
| Metric | INDSWFTLAB (Apr 24, 2026) | SAKAR (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 4.00 | 54.56 |
| Forward P/E | N/A | N/A |
| PEG Ratio | 0.05 | 0.45 |
| Price to Sales (TTM) | 2.02 | 5.89 |
| Price to Book (MRQ) | 0.84 | 4.56 |
| Market Capitalization | ||
| Market Capitalization | ₹11.98B | ₹13.91B |
| Enterprise Value | ₹7.27B | ₹14.54B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.23 | 6.28 |
| Enterprise to EBITDA | -14.12 | 25.21 |
| Risk & Other Metrics | ||
| Beta | 0.67 | 0.11 |
| Book Value per Share (MRQ) | ₹163.64 | ₹136.29 |
Financial Statements Comparison: Ind-Swift Laboratories Ltd. vs Sakar Healthcare Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | INDSWFTLAB (2025) | SAKAR (2025) |
|---|---|---|
| Revenue/Sales | 5.62B | 1.78B |
| Cost of Goods Sold | 3.38B | 823.26M |
| COGS % of Revenue | 60.2% | 46.4% |
| Gross Profit | 2.23B | 952.59M |
| Gross Margin | 39.8% | 53.6% |
| Research & Development | N/A | 6.40M |
| Operating Income (EBIT) | -416.41M | 293.42M |
| Operating Margin | -7.4% | 16.5% |
| EBITDA | 317.34M | 503.58M |
| EBITDA Margin | 5.6% | 28.4% |
| Pre-Tax Income | 2.58B | 215.27M |
| Pre-Tax Income % of Revenue | 45.9% | 12.1% |
| Income Tax | 72.70M | 40.25M |
| Income Tax % of Revenue | 1.3% | 2.3% |
| Net Income (Profit) | 2.50B | 175.02M |
| Profit Margin | 44.6% | 9.9% |
Balance Sheet & Liquidity Metrics
| Metric | INDSWFTLAB (2025) | SAKAR (2025) |
|---|---|---|
| Cash & Equivalents | 4.12B | 1.02M |
| Total Current Assets | 8.65B | 887.27M |
| Total Current Assets % of Revenue | 154.1% | 50.0% |
| Total Current Liabilities | 2.21B | 631.86M |
| Total Current Liabilities % of Revenue | 39.3% | 35.6% |
| Long-Term Debt | 259.35M | 535.94M |
| Long-Term Debt % of Revenue | 4.6% | 30.2% |
| Total Shareholders Equity | 11.73B | 2.85B |
| Retained Earnings | -1.38B | 980.38M |
| Retained Earnings % of Revenue | -24.5% | 55.2% |
| Property, Plant & Equipment | 270.23M | 449.59M |
Cash Flow Statement Comparison
| Metric | INDSWFTLAB (2025) | SAKAR (2025) |
|---|---|---|
| Operating Cash Flow | -213.52M | 223.74M |
| Operating Cash Flow % of Revenue | -3.8% | 12.6% |
| Capital Expenditures | -258.10M | -322.83M |
| Free Cash Flow | -898.80M | 17.50M |
| FCF Margin | -16.0% | 1.0% |
| Debt Repayment | -66.04M | -13.61M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | INDSWFTLAB | SAKAR |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 86.84M | 21.95M |
| Float Shares | 25.94M | 4.93M |
| % Held by Insiders | 66.37% | N/A |
| % Held by Institutions | 4.62% | N/A |
| % Held by Public | 29.01% | N/A |
Dividend Analysis & Yield Comparison: Ind-Swift Laboratories Ltd. vs Sakar Healthcare Ltd.
| Metric | INDSWFTLAB | SAKAR |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | ₹0.00 | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | ₹0.00 | N/A |
| Ex-Dividend Date | N/A | N/A |